Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review
- 1Keck School of Medicine, University of Southern California, Los Angeles, CA USA
- 2Department of Dermatology, University of Southern California, 1441 Eastlake Ave, Ezralow Tower, Suite 5301, Los Angeles, CA 90033-9174 USA
- 3Department of Internal Medicine, Division of Rheumatology, University of Southern California, Los Angeles, CA USA
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory condition that carries a high burden of comorbidities, including various autoimmune conditions. Emerging population-level data indicate a significant association between HS and lupus spectrum diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), and drug-induced lupus erythematosus (DILE), with studies demonstrating an elevated risk of SLE among patients with HS compared with non-HS controls. Despite shared immunological mechanisms, including overlapping cytokine signaling and pathways such as the Janus kinase/signal transducers and activators of transcription (JAK/STAT) cascade, co-managing HS and lupus presents major clinical challenges. Guidance on how to manage patients with both HS and varying presentations of lupus is limited in the literature. A primary management challenge is the risk of DILE or inducing flares of preexisting SLE. Tumor necrosis factor (TNF)-α inhibitors (e.g., adalimumab, infliximab), which are mainstays of treatment for moderate-to-severe HS, can induce autoantibodies and trigger DILE. Other common medications used for HS, such as minocycline, have also been associated with reports of drug-induced lupus. Managing patients with concurrent HS and lupus should balance adequate HS disease control while avoiding therapies capable of inducing or exacerbating lupus flares. Other treatment options, such as anifrolumab, interleukin (IL)-1 inhibitors, and JAK/tyrosine kinase (TYK)2 inhibitors are currently under investigation, with preliminary data supporting their role in managing both HS and lupus spectrum diseases. Herein, we propose a clinical decision framework to guide safe, individualized therapeutic strategies for clinicians treating this complex patient population.
Related
- Dietary and Nutritional Considerations for Metabolic Dysfunction-Associated Steatotic Liver Disease in Psoriasis and Hidradenitis Suppurativa: A Narrative Review
- Emotional and social burden of hidradenitis suppurativa: a qualitative multi-centre narrative medicine project in Italy
- Male-predominant, perianal-prone hidradenitis suppurativa in China: A cohort study of 614 patients.
- Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Patients with Hidradenitis Suppurativa
- Efferocytosis-Related Transcriptional Dysregulation in Hidradenitis Suppurativa Lesional Macrophages: A Multi-Cohort Single-Cell and Bulk Transcriptomic Study
BibTeX
@article{chung2026management,
title = {{Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review}},
author = {Claire S. Chung and Kenan Kherallah and Ashley B. Crew and Stratos Christianakis and Jennifer L. Hsiao and Katrina H. Lee},
journal = {Dermatology and Therapy},
year = {2026},
month = sep,
doi = {10.1007/s13555-026-01930-8},
url = {https://doi.org/10.1007/s13555-026-01930-8},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review
AU - Claire S. Chung
AU - Kenan Kherallah
AU - Ashley B. Crew
AU - Stratos Christianakis
AU - Jennifer L. Hsiao
AU - Katrina H. Lee
PY - 2026
DA - 2026/09/01
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01930-8
UR - https://doi.org/10.1007/s13555-026-01930-8
AB - Hidradenitis suppurativa (HS) is a chronic inflammatory condition that carries a high burden of comorbidities, including various autoimmune conditions. Emerging population-level data indicate a significant association between HS and lupus spectrum diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), and drug-induced lupus erythematosus (DILE), with studies demonstrating an elevated risk of SLE among patients with HS compared with non-HS controls. Despite shared immunological mechanisms, including overlapping cytokine signaling and pathways such as the Janus kinase/signal transducers and activators of transcription (JAK/STAT) cascade, co-managing HS and lupus presents major clinical challenges. Guidance on how to manage patients with both HS and varying presentations of lupus is limited in the literature. A primary management challenge is the risk of DILE or inducing flares of preexisting SLE. Tumor necrosis factor (TNF)-α inhibitors (e.g., adalimumab, infliximab), which are mainstays of treatment for moderate-to-severe HS, can induce autoantibodies and trigger DILE. Other common medications used for HS, such as minocycline, have also been associated with reports of drug-induced lupus. Managing patients with concurrent HS and lupus should balance adequate HS disease control while avoiding therapies capable of inducing or exacerbating lupus flares. Other treatment options, such as anifrolumab, interleukin (IL)-1 inhibitors, and JAK/tyrosine kinase (TYK)2 inhibitors are currently under investigation, with preliminary data supporting their role in managing both HS and lupus spectrum diseases. Herein, we propose a clinical decision framework to guide safe, individualized therapeutic strategies for clinicians treating this complex patient population.
SN - 2193-8210
SN - 2190-9172
ER -